Nuclear Medicine Unit, Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, University of Messina, 98125 Messina, Italy.
Department of Nuclear Medicine, University Hospital Zürich, University of Zürich, 8091 Zürich, Switzerland.
Tomography. 2022 Sep 30;8(5):2471-2474. doi: 10.3390/tomography8050205.
For prostate cancer (PCa) biochemical recurrence (BCR), the primarily suggested imaging technique by the European Association of Urology (EAU) guidelines is prostate-specific membrane antigen (PSMA) positron emission tomography/computer tomography (PET/CT). Indeed, the increased detection rate of PSMA PET/CT for early BCR has led to a fast and wide acceptance of this novel technology. However, PCa is a very heterogeneous disease, not always easily assessable with the highly specific PSMA PET with around 10% of cases occuring without PSMA expression. In this paper, we present the case of a patient with PCa BCR that resulted negative on [Ga]Ga-PSMA-11 PET/CT, but positive on [F]Fluoromethylcholine (Choline) PET/CT.
对于前列腺癌(PCa)生化复发(BCR),欧洲泌尿外科学会(EAU)指南主要推荐使用前列腺特异性膜抗原(PSMA)正电子发射断层扫描/计算机断层扫描(PET/CT)进行影像学检查。事实上,PSMA PET/CT 对早期 BCR 的检测率增加,导致这项新技术得到了快速广泛的认可。然而,PCa 是一种非常异质的疾病,并非总是可以用高度特异性的 PSMA PET 轻易评估,约有 10%的病例不表达 PSMA。本文报告了一例 PCa BCR 患者,[Ga]Ga-PSMA-11 PET/CT 结果为阴性,但[F]氟甲基胆碱(Choline)PET/CT 结果为阳性。